MedPath

Optical CoherenCe tomography-gUided coronary intervention in Patients with complex lesIons: a randomized controlled trial (OCCUPI trial)

Not Applicable
Completed
Conditions
Diseases of the circulatory system
Registration Number
KCT0003325
Lead Sponsor
Yonsei University Health System, Severance Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
1604
Inclusion Criteria

Age 19-85 years
- Patients with ischemic heart diseases (including stable angina, unstable angina and acute myocardial infarction) presented with typical chest pain or objective evidences of myocardial ischemia (positive invasive or non-invasive studies,
electrocardiogram (ECG) consistent with ischemia, or elevated cardiac enzymes)
- Complex coronary stenotic lesions (>50% based on visual estimate) considered for coronary revascularization with DES
- Definition of complex lesions (at least one):
? Acute myocardial infarction
? Chronic total occlusion
? Long lesion: expected stent length =28mm based on angiographic estimation
? Calcified lesion
? Bifurcation (including all techniques, one- or two-stent)
? Unprotected left main disease
? Small vessel diseases with reference vessel diameter less than 2.5 mm
? Intracoronary thrombus visible on the angiography
? Stent thrombosis
? In-stent restenosis
- Patients who provide signed informed consent

Exclusion Criteria

- Severe hepatic dysfunction (=3 times normal reference values)
- Significant renal dysfunction (Serum creatinine >2.0 mg/dL)
- Platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a white blood cell count of <3,000 cells/mm3, hemoglobin <8.0 g/dL, or other known bleeding diathesis
- Hemodynamically unstable during procedures or cardiogenic shock
- Pregnant women or women who might be pregnant
- Life expectancy; less than 1 year
- Inability to understand or read the informed content

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MACE (major adverse cardiac event)
Secondary Outcome Measures
NameTimeMethod
Each component of MACE(major adverse cardiac event);Target lesion revascularization;Periprocedural myocardial infarction;Bleeding;Any revascularization;Stroke;Stent thrombosis confirmed by OCT;Contrast-induced Nephropathy
© Copyright 2025. All Rights Reserved by MedPath